AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06205914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation of patella fractures by craniofacial mesh plate osteosynthesis augmented by screws
Description: patellar fracture fixation using MatrixNEURO Contourable Mesh plates (Synthes®). Made of titanium with an incredibly low profile
Study NCT06204627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham TDCS
Description: TDCS sham: The device remains inactive for 20 minutes.
Study NCT06204627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham TDCS
Description: TDCS sham: The device remains inactive for 20 minutes.
Study NCT06204627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Landscape recognition
Description: Image recognition training that does not refer to right/left discrimination.
Study NCT06204627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Landscape recognition
Description: Image recognition training that does not refer to right/left discrimination.
Study NCT05337410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YES IDEAS
Description: YES IDEAS is an adapted version of the evidence based YES (Youth Empowerment Solutions) program. Through the YES program, youth design and implement their own projects to help improve their own communities. The adapted YES IDEAS curriculum empowers youth from diverse backgrounds to address racism and racial discrimination as a way to reduce violent behavior. Over the course of the program, youth carry out a community change project aimed at promoting inclusion, diversity, equity, appreciation, and solidarity in their community.
Study NCT06352710 — intervention group
Intervention type: OTHER
Intervention: OP-Tracker App
Description: There will be no study-specific therapeutic intervention. The OP-Tracker App will be downloaded and installed on the patient's smartphone. Preoperative assessment: baseline factors such as age, gender, medical conditions, type of disease and of surgery, EQ-5D-5L. Before and after surgery surgery, SWI (Quality of life) will be assessed daily using pop-ups; the patient will input the value (0-10) using a slide-bar. After completion of the surgery, the app will automatically modify the number of SWI assessments over time according to the occurrence of AEs. At any point in time, the patient will be able to register an AE in the smartphone app. The patient can select the AE via a drop-down menu in the app, and can additionally input free text in case of an AE of type other. Using a further drop-down menu, the patient will classify the AE according to the CDG and TDN grade. QoL assessments (EQ-5D-5L questionnaire) will pop up before, and at 3 and 12 months after surgery.
Study NCT06219759 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study.
Study NCT06172699 — intervention group
Intervention type: DEVICE
Intervention: Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
Description: All enrolled subjects who meet eligibility criteria will undergo an attempted implant within 30 days of consent. After successful device implant, subjects will be followed at 1 and 12 months. Subjects will be fitted with a Holter monitor during the 1m follow-up visit and will complete a minimum of 72 hours and maximum of up to 7 days of Holter monitoring.
Study NCT04980833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
Study NCT06536361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Based Learning Tool
Description: The intervention involves the use of a virtual reality-based learning tool to teach thorax and lung physical examination skills. The tool uses Oculus Meta Quest 3 VR headset to provide immersive simulation experiences. The VR tool includes high-quality graphics and interactive scenarios to facilitate skill development.
Study NCT06536361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Small Group Training
Description: The intervention involves traditional small group training conducted in the Nursing Principles Skills Laboratory. This training includes hands-on practice with physical examination techniques using simulation mannequins and feedback from instructors. The approach is designed to provide practical experience without the use of virtual reality technology.
Study NCT06577844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video support
Description: video support provided to the patient before surgery
Study NCT05668208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-CUBE i7 ultrasound system (Alpinion Medical Systems, Seoul, Republic of Korea)
Description: ONSD measurement will be made using the E-CUBE i7 ultrasound system.
Study NCT05668208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-CUBE i7 ultrasound system (Alpinion Medical Systems, Seoul, Republic of Korea)
Description: ONSD measurement will be made using the E-CUBE i7 ultrasound system.
Study NCT06102941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CT)
Description: 4 weeks of an at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes.
Study NCT06345027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment Arm A
Description: Each patient will receive one T cell infusion.~CD70.CAR Dose Levels / Cell Dose (transduced cells):~Dose Level -1: 3 x 10\^5 cells/kg Dose Level 1 (starting dose level): 1 x 10\^6 cells/kg Dose Level 2: 3 x 10\^6 cells/kg Dose Level 3: 1 x 10\^7 cells/kg~\*First three patients treated on the study will be adults 18 years of age or older.
Study NCT05879289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A power supplement
Description: A dietary supplement containing vitamins and collagen
Study NCT05695612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novaloc Attachment
Description: Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Novaloc attachments. The proper Novaloc abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
Study NCT05695612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Locator Attachment
Description: Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Locator attachments. The proper Locator abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
Study NCT05463796 — intervention group
Intervention type: OTHER
Intervention: Samples
Description: Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues
Study NCT05037201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message
Description: The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
Study NCT05408299 — intervention group
Intervention type: BIOLOGICAL
Intervention: Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)
Description: Vaccination
Study NCT04693208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Laser treatment parameters will be two combined wavelength (660 and 970 nm), 3.2 Watt peak power, 320 milliWatt/cm2, 36.8 Joule/cm2 fluency, and 50% frequency, for a total time of 3 minutes for each site
Study NCT05884736 — intervention group
Intervention type: OTHER
Intervention: Neuromonitoring
Description: Multimodal neuromonitoring will include: Transcranial colour-coded Doppler (TCCD), Electroencephalography (EEG), and Somatosensory evoked potentials (SSEP) or brainstem auditory evoked potentials (BAEP)
Study NCT06577974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined contraceptive pills (Yasmin)
Description: medical pretreatment prior to ICSI
Study NCT06577246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling root planing
Description: periodontal treatment in all groups was performed using ultrasonic and hand instruments (#15/30, #6/7) by the same physician (UGE) who was blind to the study groups.
Study NCT06577246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling root planing
Description: periodontal treatment in all groups was performed using ultrasonic and hand instruments (#15/30, #6/7) by the same physician (UGE) who was blind to the study groups.
Study NCT06577246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Animation (video1-2)
Description: The video used in the study was created by DentalMaster (MD Stimulation Ltd) by combining their own footage (http://www.mdsimulation.com/). This video is divided into three parts, summarized below:~* i. Overview of the causes and symptoms of periodontal disease (section 1)~* ii. Treatment of periodontal disease and daily oral care practices for individuals (section 2)
Study NCT06577246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-Dimensional Animation (video1-2)
Description: The video used in the study was created by DentalMaster (MD Stimulation Ltd) by combining their own footage (http://www.mdsimulation.com/). This video is divided into three parts, summarized below:~* i. Overview of the causes and symptoms of periodontal disease (section 1)~* ii. Treatment of periodontal disease and daily oral care practices for individuals (section 2)
Study NCT06577246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-Dimensional Animation (video 3)
Description: iii.Consequences of periodontal disease (such as gingival recession and tooth loss) that individuals may face if periodontal diseases are not treated and if they do not perform regular oral care (section 3). In this group, patients watch the video together with the physician (SG), who is familiar with the randomized patient groups.
Study NCT06577246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Periodontal Disease Prediction (PDP)
Description: The patients in the test group viewed sections 1 and 2 videos in the same manner as the 3DA group. However, unlike the 3DA group, they did not view section 3. Instead, they were shown estimates of their current condition and potential future periodontal tissue loss (gingival recession) for 1-5 years, 5-10 years, and 10-20 years. These projections were presented to the patients in three dimensions with PDP visualisation.
Study NCT06159842 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid 20% Topical Solution with Blue Light
Description: Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
Study NCT06431932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Subjects will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.
Study NCT06431932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a corresponding number of placebo capsules for two consecutive days.
Study NCT04987320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Subcutaneous injection
Study NCT06087809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and feedback
Description: Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email.
Study NCT05616650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Each participant will receive a single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi; dose variations will be in accordance with the Nuclear Regulatory Commission (NRC) standard dose variation (i.e., 20%) permitted for diagnostic clinical studies.
Study NCT05710653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training intervention
Description: The intervention will consist in adhering to high-intensity interval training and/or resistance training three times a week
Study NCT05616650 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Intensity modulated radiotherapy will be delivered to a dose of 26Gy in two fractions with the second fraction performed within 8 days of the first session.
Study NCT06632457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Subcutaneous injection
Study NCT04955405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The seven visit telemedicine protocol
Description: The transition of care team (pharmacist, advanced practice provider, social worker) will conduct an initial visit as a team with the patient using the telemedicine platform. During the visit, the team will assess the clinical, social, and pharmaceutical needs of the patient. The transition of care team will then meet to discuss the specific needs of the patient and to develop a care plan for the next 6 telemedicine visits. Either the social worker or the advanced practice provider will conduct the next 6 visits. The pharmacist will provide medication counseling as needed and recommended by the entire care team. The next 3 visits will occur weekly, the following 2 visits will occur biweekly, and the remaining 1 visit will occur at some point during the third month.
Study NCT05270577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: prehabilitation
Study NCT05270577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: No intervention
Study NCT06632457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching survodutide
Description: Subcutaneous injection
Study NCT06087809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration.
Study NCT00622141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: generic GPO saquinavir and novir vs invirase and norvir
Description: Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
Study NCT04826081 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: data collection
Study NCT06578572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21Matrix M
Description: A mixture of R21/Matrix M at a dose of 5 μg (for children up to 14 years of age) or 10 μg ( for individuals ≥ 15 years old) with 50 μg of Matrix-M will be administered monthly over 3 months (one dose per month over 3 months (May, June, and July 2024) plus a booster dose in June 2025.
Study NCT06578260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support groups with a solution-focused approach
Description: To investigate the effectiveness of a support group intervention using a solution-focused approach among school children in 5th-7th grade in southeastern Norway
Study NCT04787913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: herdimm
Description: In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
Study NCT04787913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: guardianmeasles
Description: A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated
Study NCT04787913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: theotheredmundmeasles
Description: A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4
Study NCT04787913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sbsnewsgeneric
Description: A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles
Study NCT04787913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: publichealthagencycanadaflu
Description: A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html
Study NCT04787913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: robertkochgeneric
Description: A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
Study NCT04967924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular training
Description: Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)
Study NCT04967924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sports specific training
Description: Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
Study NCT06060691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaempferol
Description: Kaempferol
Study NCT03985501 — intervention group
Intervention type: OTHER
Intervention: SCD newborn screening with the MS/MS method from Zentech
Description: The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)
Study NCT04303845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 140 mg of erenumab via subcutaneous injection
Study NCT05261516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.
Study NCT05261516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.
Study NCT04432610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol versus Nebivolol
Description: All subjects will receive both drugs, but at different time periods determined by randomization, with 1 week washout period